The purpose of this study is to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face (Upper Facial Lines \[UFL\]): Horizontal Forehead Lines \[HFL\], Glabellar Frown Lines \[GFL\], and Lateral Canthal Lines \[LCL\]). It is a prospective, randomized, double-blind, placebo-controlled, multicenter study with a placebo-control main period (MP) followed by an open-label extension (OLEX) period.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30
Timeframe: Day 30
Main Period: Percentage of Horizontal Forehead Lines (HFL) Responders at Day 30
Timeframe: Day 30
Main Period: Percentage of Lateral Canthal Lines (LCL) Responders at Day 30
Timeframe: Day 30